Vectors derived from adeno-associated virus (AAV) are currently the most promising vehicles for therapeutic gene delivery to the retina. Recently, subretinal administration of AAV2 has been demonstrated to be safe and effective in patients with a rare form of inherited childhood blindness, suggesting that AAV-mediated retinal gene therapy may be successfully extended to other blinding conditions. This is further supported by the great versatility of AAV as a vector platform as there are a large number of AAV variants and many of these have unique transduction characteristics useful for targeting different cell types in the retina including glia, epithelium and many types of neurons. Naturally occurring, rationally designed or in vitro evolved AAV vectors are currently being utilized to transduce several different cell types in the retina and to treat a variety of animal models of retinal disease. The continuous and creative development of AAV vectors provides opportunities to overcome existing challenges in retinal gene therapy such as efficient transfer of genes exceeding AAV's cargo capacity, or the targeting of specific cells within the retina or transduction of photoreceptors following routinely used intravitreal injections. Such developments should ultimately advance the treatment of a wide range of blinding retinal conditions.
INTRODUCTION
Adeno-associated virus (AAV) was first identified as a potentially useful vector for gene transfer in the early 1980s by pioneering work on AAV serotype 2 in the laboratories of Drs Carter and Muzyczka. [1] [2] [3] [4] Several aspects of the natural biology of the virus appeared attractive for somatic gene transfer; the virus is not associated with human disease, its small genome was molecularly cloned and could fairly readily be manipulated in vitro, and the virus is able to transduce terminally differentiated, non-dividing cells. 5 The exploration of AAV as a gene transfer vector highlighted even more interesting properties; AAV requires only the terminal repeats in cis for genome packaging and particle assembly, eliminating all viral-coding DNA from the vector genome and thereby reducing its immunogenicity and freeing up more room for genetic cargo. And, as was established in later research, every base pair counts, as AAV's size limitation is one of its biggest limitations for its use in gene therapy, including its ocular applications.
The potential benefits of AAV vectors justified their early application in clinical trials of gene therapy for cystic fibrosis and hemophilia B. 6 However, these trials did not demonstrate functionally significant levels of gene transfer, and there was no evidence for therapeutic or clinical benefit. AAV serotype 2, though an excellent gene transfer vector for transducing certain cells (for example, hepatocytes, the retinal pigment epithelium (RPE) or retinal ganglion cells), was found to be too inefficient for transducing many other cell types, for example, photoreceptors (PRs). 7 Second, AAV2 neutralizing antibodies, directed to epitopes on the viral capsid, were found to be prevalent in human population due to prior exposure to the natural virus, and potentially block vector transduction. 8 These concerns prompted a search for alternatives for AAV2 that could overcome the deficits, yet preserve the benefits of the platform. This was facilitated by the genetics of AAV in that it allowed cross-packaging of AAV2-based genomes with an alternative capsid shell. 9 
AAV CAPSID SEROTYPES, ISOLATES AND MUTANTS: NATURE VERSUS NURTURE
AAV contains a single-stranded DNA genome packed in an icosahedral capsid comprised of three structural Cap proteins (VP1, -2 and -3). The particle is largely made up by numerous copies of the 60 kDa AAV VP3 protein. However, for every 10 VP3 molecules, one VP1 and one VP2 capsid monomer (whose C-terminal sequence is identical to VP3) is anchored in the virion architecture. 5 The first alternative capsids that were evaluated by cross-packaging with AAV2 genomes were the capsids from various natural serotypes, many of which were isolated sometime between 1950 and 1990 and molecularly cloned over the last 10 years (reviewed in Gao et al. 7 ). These serotypes, AAV1 through six (sometimes referred to as the AAV 6-pack), provided remarkable potential compared with AAV2 in terms of tropism and transduction efficiency in murine models, for example, AAV1 in the muscle and AAV5 in the central nervous system. Motivated by these findings, the group of Dr James M Wilson at the University of Pennsylvania, isolated latent AAV from non-human primate (NHP) and human tissues by PCR and identified over 120 novel AAV isolates clustered in six viral clades, four of which were previously uncharacterized. Three serotype vectors, AAV7, 8 and 9 and some of the vectors based on isolates from these studies provided even greater potential in terms of levels of transgene expression in several important therapeutic targets such as the liver, muscle and retina. Other groups have focused attention on non-primate sources of AAV and have characterized AAVs endemic in cow, pig, bird, goat and mouse. [10] [11] [12] [13] [14] A growing number of AAV serotypes have been resolved structurally 15, 16 and the improved understanding of the structure-function relationship of the virion has provided the means to develop rational approaches to altering the capsid in silico and in vitro. A primary ambition of these strategies is to tailor the vector for a particular therapeutic goal, for example by enhancing its gene transfer efficiency, altering its cell specificity, improving its safety profile or combining desired phenotypes from more than one serotype. This ambition is shared by an another method of capsid engineering, referred to as directed evolution of AAV. Briefly, in directed evolution, a large library of laboratory-generated capsid variants is subjected to pressure by applying conditions selective for the desired vector phenotype. The technique thereby does not require a thorough understanding of AAV's structure-function biology or protein engineering, as it is unbiased in its approach. Both directed evolution and rational design strategies for AAV were reviewed elsewhere, 8 and here we will restrict our discussion to those engineered constructs that have been evaluated in the retina.
First, in a rational design effort, the Srivastava group aimed at intracellular redirection of AAV particles away from the proteasome, to accomplish higher levels of transduction at lower doses. Basic trafficking studies suggested that capsid tyrosine residues could be phosphorylated, pre-destining them for ubiquitination and eventual proteosome degradation. On the basis of the available structural data on AAV serotypes, site-directed mutagenesis of one or more tyrosines to phenylalanine indeed increased gene transfer efficiency in various in vivo and in vitro settings. 17, 18 Initial proof-of-concept of this exciting approach was established with AAV2, but has now been extended to multiple other serotypes including AAV8. 18 Data from these studies demonstrated in murine models marked enhancement of retinal transduction following intraocular delivery. Which tyrosine residue mutation is optimal for an individual serotype requires empirical evaluation but for AAV2-Y444F, AAV2-Y730F, AAV8-Y733F and AAV9-Y446F a reduced dose requirement, broader tropism within the neuronal retina and enhanced diffusion across the retina were noted in the mouse model. 18 More recently, AAV2 variants with multiple tyrosine mutations further demonstrated improvements in retinal transduction and diffusion following subretinal and intravitreal delivery. 19 Importantly, an AAV8-Y733F encoding guanosine monophosphate-phosphodiesterase was shown to rescue long-term function and structure rescue of disease in rd10 mice, a particularly challenging model for autosomal recessive RP. 20 A second example of the potential of structure-function based engineering of the AAV capsid came from the study of the wealth of sequence information obtained on the AAV virome. Unique capsid residues were identified in AAV isolates from human and NHP tissues that were not shared by homologous AAVs. These proviral singleton residues were thought to be failed attempts by the virus to enhance its fitness and this hypothesis was challenged by altering them to the residue shared by its related partners. 8 In some cases, singleton-reversed particles demonstrated improved transducing ability, but its main effect was seen in marked increases in titer, likely due to increased structural stability during viral assembly. Taken together, these rational design approaches expanded the AAV toolbox with a set of dozens of novel gene transfer reagents that require evaluation in all relevant therapeutic target organs, including the retina.
Many groups have pursued directed evolution as a means to select AAVs derived from combinatorial libraries (reviewed by Perabo et al. 21 ), but only a few groups have brought this approach to the retina, or cell types relevant to the retina. The groups of David Schaffer and John Flannery did, however, take this approach to identify AAVs with improved glial tropism from a panel of libraries generated in his laboratory. Multiple rounds of selection on cultured primary human astrocytes yielded a number of candidate vectors, which next underwent confirmatory screening in vivo for their ability to target astrocytes in the rat central nervous system. These experiments yielded two AAV2 variants named ShH19 and L1-12 and the AAV6-like ShH10 with substantially more astrocyte transduction in comparison to AAV2 and AAV6 controls. These observation led them to explore the potential of these vectors in the retina where ShH10 demonstrated an improved tropism for Müller cells via intravitreal injection. 22, 23 AAV TARGETING IN THE RETINA: A FUNCTION OF DOSE, ADMINISTRATION ROUTE, DISEASE STATE, ANIMAL MODEL, AND CAPSID The viral capsid is not the only determinant of the specificity or efficacy of retinal cell transduction; several other factors affect AAV-mediated gene transfer to the retina. AAV vectors often have a broad tropism, but their targeting can be steered by their route of administration or site of delivery. This is true for the retina where the two main vector delivery approaches are intravitreal and subretinal injection. The intravitreal route deposits the vector dose in the vitreous. 24 With the advent of anti-angiogenic therapies that are administered through intravitreal injections, these procedures are now very routine clinical ophthalmologic interventions. Intravitreal injection of AAV2 vectors results in efficient transduction of retinal ganglion cells. 25 No other AAV serotypes (at least those with unmodified capsids-see later) appear to transduce the retina following intravitreal injection. A second type of vector delivery deposits the vector below the retina, in a virtual space between the RPE and the PR called the subretinal space. Subretinal administrations of vectors induce a regional retinal detachment called bleb, which flattens within hours or days following vector uptake and diffusion of the diluent. 24 In humans and large animals the procedure is usually performed with a (partial) vitrectomy to provide more volume for the vector-containing solution and to relieve ocular pressure. In rodents, it is not possible to carry out a vitrectomy, but subretinal injections are performed adequately without them. Subretinal injections, both clinically and in large and small animal models, are technically more challenging than intraviteal injections and have a higher potential for surgical morbidity. However, to date it is the most efficient method for targeting PRs and RPE cells, which are the most relevant cell types for treating many forms of inherited blindness. Subretinal injection of any of the AAV serotypes tested to date can result in very efficient transduction of RPE (usually 100% transduction in the area of detachment) and variable transduction of PRs (between 20 and 80% depending, on the serotype and titre used 26 -see later). Although the growing experience in vitreo-retinal surgery raised the acceptability of subretinal injections as a procedure for gene therapy applications an intravitreal approach, which distributes vector, allow more homogenous transduction and pose a lower risk of surgical complications, would be greatly preferred. For this reason the field is actively pursuing vectors that enable transduction across the retina from the vitreal side. Advances are being made in the understanding of the structural and biochemical barriers that must be overcome to make to make this happen. Dalkara et al. 23 demonstrated elegantly how the vitreoretinal junction is a serotype-specific hurdle for AAV, and the authors speculate the abundance of AAV serotype receptors on the inner limiting is a factor in limiting the diffusion across this barrier. 18 Novel vectors, such as the multiple tyrosine mutants of AAV2, 19 are emerging for which diffusion does not appear to be hampered and they show significant potential to transduce RPE and PR following intravitreal injection in small animals. However, it remains to be seen whether the efficiencies of gene transfer are sufficient for therapeutic gene delivery to these cells, and if intravitreal injection of these vectors is effective in large animal models where there are more pronounced physical barriers between the vitreous and inner retina. In addition, recent studies highlight an increased risk of systemic vector dissemination and immune activation following intravitreal administration of vector, possibly limiting its use for gene therapy. 27, 28 Of the several clinical trials, underway or completed, that are using AAV2 to treat retinal diseases, three have used subretinal injection to target RPE cells in order to treat a form of Lebers congenital amaurosis (LCA2) 27, 29, 30 and one is using intravitreal injection for the delivery of an anti-angiogenic molecule, sFLT, aimed at treating the neovascular complications of age-related macular degeneration. 28 With several translational programs underway in AAV-based ocular gene therapy, increased emphasis is being placed on determining dose requirements, therapeutic thresholds and dose-limiting toxicity. In human trials, the maximum reported dose that has been used to date is 1.5Â10 11 particles and was found to be safe and well tolerated and in the absence of notable cellular or humoral immune responses to vector or transgene. 31 In animals, much higher doses have been administered, in part to achieve the highest level of transgene expression and in part to target less permissive retinal cell types. From a literature survey, the highest dose injected subretinally in animal models is 2.7Â10 13 particles for NHP 32 and 6.4Â10 13 for dogs, 33 both, though not specifically monitored for, in the apparent absence of immune sequelae. Other studies, in both NHP and dogs, indicate that elevated AAV doses do lead to toxic or inflammatory responses to the gene transfer, although it is unclear whether this is related to vector dose or the high level of expression. 26, 34 In mice and rats subretinal injections of doses as high as 5Â10 10 and 1Â10 12 particles, 35 respectively are well tolerated. A subretinal dosing study with AAV2 and AAV8 in NHPs highlighted the importance of dose and vector targeting; low doses targeted RPE exclusively where higher doses were required to transduce PRs. Cone PRs prove to be particularly refractory to AAV transduction, which can be overcome in part by elevating vector dose 26 and switching serotype. Lastly, an important dose-related aspect of translating retinal gene therapies to the clinic, is repeat administration. Most forms of retinal degeneration, particularly the inherited forms, affect both eyes and ideally, will require a bilateral injection. There are a number of parameters that make this procedure quite complex. First, two injections doubles the dose of vector administered to the subject. Second, unless the injections are performed simultaneously, which is impractical and unlikely, the first injection, and the nature of the immune response thereof, may impact the safety and/efficacy of the second. Finally, the interval between the first and the repeat injection is anticipated to have a role qualitatively as well as quantitatively in terms of host response to the second injection. This complexity poses a difficulty for both clinician-investigators and regulators to navigate through as is evidenced by a recent symposium organized by the US Food and Drug Administration Advisory Committee on Cellular, Tissue and Gene Therapies on this topic. 36 Ocular re-adminstration of AAV has been studied for bilateral subretinal injection in mouse, 37 dog 38 and monkey. 39 Overall, these studies show safe and efficient gene transfer of both eyes for the conditions tested. Neutralizing antibodies to AAV do arise following the first injection, but where these may interfere with transduction of the contralateral eye in mice (at higher doses), this was not observed in dogs or NHPs.
AAV vector transduction characteristics may also be impacted by the host species and the health of the retina. This is exemplified by two sets of observations. First, cone PR targeting by AAV2 has been described in the canine retina. 40 However, in NHPs cone transduction was not observed even at higher doses, indicating a species-specific serotype tropism. 41 Second, broad transduction of the neuronal retina via an intravitreal route of injection is difficult and remains a major challenge for the field, although intravitreal injection of AAV2 and AAV8 vectors in a murine model of retinoschisis have been shown to result in robust transduction of the neuroretina, probably due to disrupted retinal lamination. The contrasting results in these examples are likely attributable to anatomical and/or biochemical differences between hosts that affect vector diffusion and or the availability of the cognate receptor for the particular AAV serotype. In an elegant report, Flannery's laboratory described how differences in the structural and biochemical makeup between normal and diseased retinas impact the diffusion of AAV serotypes following intravitreal injection. Data shows that the cell types in inner retina become much more accessible for AAV during retinal degeneration, 23 an observation that they attribute to the concomitant disorganization of the inner limiting membrane (ILM). 23 However, this does not apply to all types of retinal degeneration as outer retina targeting via intravitreal administration of AAV is poor in the rd10 model of retinitis pigmentosa. 42 GETTING TO THE RETINAL SWITCH: AAV-MEDIATED PR TRANSDUCTION Inherited retinal degenerations (IRDs) with an overall prevalence of 1/2000 worldwide 43 are a major cause of blindness and affect over 200 000 people in the European Union. Among the most frequent and severe forms of IRD are recessive retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) and Stargardt disease (SD). RP, LCA and SD, as with other forms IRDs, are characterized by loss of neuronal PR, rods and/or cones in the retina. 44 Independent of the disease causing mutations, PR loss occurs by apoptosis. 44 The majority of mutations causing IRDs occur in genes expressed in PR. 44 Thus efficient gene transfer to PR is key for treatment of most of these blinding conditions. The first evidence that AAV targets PR in addition to the RPE was provided by the group of Robin Ali. 45 Since then, several groups have shown that AAV2 transduces PR of various species including NHP 26, 41 and dogs 46 upon subretinal administration. Indeed, therapeutic efficacy, albeit transient, has been observed upon AAV2 subretinal administration in rds mice, a model of RP 47 and in other IRD models [48] [49] [50] due to mutations in genes expressed in PR. The possibility of swapping capsids with ease between different AAV serotypes provided access to a portfolio of novel recombinant AAV vectors, and the search for improved PR targeting AAVs began. In mice, AAV5 immediately appeared superior to AAV2 (refs 9, 52, 53) as it fairly efficiently targeted PR at higher levels than was previously seen with AAV2. Also, its onset of expression was faster by about a week. The group of Beverly Davidson has shown that AAV5 transduces efficiently NHP rod, but not cone PR. 53 Soon, robust proof-of-concept was provided of AAV5-mediated gene supplementation therapy in animal models of IRD caused by defects in genes expressed in PRs. 54, 55 The Hauswirth group has additionally demonstrated the ability of AAV5 to transduce cone PR with elevated doses and cone-specific promoters in dogs 33 and NHP 32 models of achromatopsia. Despite some promising short-term improvements, 56 gene supplementation using AAV5 has not been very effective at rescuing the severe PR degeneration found in the rd10 murine model of RP, in which PR degeneration is due to partial deficiency of the beta subunit of phosphodiesterase, a key enzyme in the phototransduction cascade. 57 The contrasting results achieved with AAV5 in the different disease models likely illustrate AAV5's ability to target PR but does so insufficiently efficient for the more severe and progressive models of retinal degeneration such as in the rd10 mice. This may be due to the difficulty in achieving sufficient or appropriate levels of transgene expression despite efficient levels of PR transduction. In recent years, AAV8 has emerged, among the naturally-occurring AAV serotypes, as providing the highest levels of PR transduction in several species. In mice, we and others demonstrated AAV8's superior ability to transduce PRs efficiently, fast and delivering high transgene levels as compared with AAV5. 58, 59 We also demonstrated that AAV7, and to a lesser extent AAV9, are good candidates for targeting PRs in the mouse. 59 A side-by-side comparison in pigs 60 demonstrated higher PR transduction with subretinally administered AAV8 versus AAV5. High levels of AAV8-mediated PR transduction have been further observed in dogs. 61 In NHP, these findings from mouse, pig and dog were basically confirmed and highlighted AAV8's potential for PR gene targeting; AAV2 also demonstrated PR targeting but did so only at a 10-fold higher dose than AAV8. At moderate doses, rods, but not cones, are efficiently transduced by AAV8; whereas at higher doses rod and to some extent also cones are targeted. 26 The level of PR preservation in rd10 mice following AAV8-mediated gene supplementation therapy was superior to that obtained using an AAV5 vector, 42 although the rescue was still relatively modest compared with those achieved using AAV5 vectors in more stationary disorders. 54, 55 More effective rescue of the rd10 mouse was achieved in a study using AAV8 vectors with Tyr to Phe mutagenesis of some capsid residues. Although this study achieved the first long-term morphological and functional rescue of the rd10 mouse, 62 it was not clear whether this was due to improved efficacy due to the altered capsid, or whether it was because the treated animals were dark reared, which slows degeneration substantially; there was no direct comparison using AAV8 vectors with unaltered capsids. Other studies using AAV8 vectors include very effective gene supplementation therapy in a mouse model of achromatopsia due to CNGB3 deficiency 63 and a mouse model of LCA type 1, caused by GC1 deficiency. 64 AAV8 vectors have also been used for gene supplementation therapy to rescue function and slow degeneration in a mouse model of LCA type 4 caused by the Aipl1 deficiency. 50 The Aipl1À/À mouse has the most severe PR degeneration of any model, and rescue of this model using an AAV8 vector perhaps provides the strongest indication that AAV8 vectors might be superior to other vectors for transduction of RPs. Although yet to be established, clinical proof-of-concept rescue of PR-specific IRD appears achievable given the levels of PR transduction and rescue obtained in animal models to date.
A major remaining challenge is using AAV, a vector well known for its limited cargo capacity, to mediate the safe and efficient delivery of large genes (that is, 45 kb in size) to PRs. Attempts have been made to package into AAV capsids cDNAs from genes mutated in IRDs exceeding the wild type AAV genome size, that is, ABCA4 (mutated in SD) and MYO7A (mutated in Usher Syndrome type IB). 65 Subretinal administrations of these 'over sized' AAV vectors derived from AAV5 resulted in expression of proteins of the expected size and in significant phenotypic improvement of a mouse model of SD, the most common form of inherited macular degeneration in humans. However, the mechanism underlying over sized AAV-mediated PR transduction remains elusive as the genomes contained in over sized AAV vectors appear highly heterogeneous in size and are predominantly shorter than expected. 66 Whether ABCA4 or MYO7A transgene products produced by over sized AAV5 preparations mainly result from the re-assembly of truncated packaged genomes 66 or are derived from a minor subset of vectors in which large genomes have been observed (Sommella and Auricchio, unpublished results) has yet to be demonstrated. Irrespective of the mechanism by which the large transgene products are generated, the high heterogeneity of oversized AAV genomes remains a major limitation, frustrating efforts to progress this promising approach towards the clinic.
AAV-MEDIATED GENE TRANSFER TO THE RPE: THE FIRST CLINICAL SUCCESS OF OCULAR GENE THERAPY
Virtually all AAV serotypes tested by subretinal administration transduce the RPE efficiently. Whether this is due to an inherent permissiveness of the RPE to AAV infection (that is, the presence of AAV receptors and co-receptors at the RPE cell membrane) or is due to the phagocytic properties of the RPE that could facilitate entry of AAV particles is not clear. However, efficient AAV2-mediated RPE transduction in the Royal College of Surgeon rat, a model of RP caused by deficient RPE phagocytic activity, partly argues against this latter hypothesis. 67 Although the majority of AAV serotypes transduce additional cell types in addition to the RPE (that is, AAV2, 5, 7 and 8 transduce PR, 9, 45, 59 AAV1 transduces cells in the INL 9 ), AAV2/4 transduces exclusively the RPE of various species. 68 Several proof-of-concept studies of AAV-mediated correction of RPE-specific IRDs have been provided in the last decade (for review see Stieger et al 69 ). Among these, the most successful have been the restoration of vision obtained following subretinal administrations of AAV2 in the Briard dog model of LCA type 2 (LCA2) due to mutations in RPE65, encoding the RPE-specific all-trans retinol isomerase. 46 This extraordinary result initially obtained by a group of investigators coordinated by Jean Bennett at the University of Pennsylvania and then replicated by several other groups [70] [71] [72] has opened the doors to three independent clinical trials testing the safety and efficacy of subretinal administrations of AAV2 in LCA2 patients. 27, 29, 30 Although a detailed discussion of the results from these trials is beyond the scope of this review, some important conclusions can be drawn from these studies: (i) AAV2 subretinal administration appears safe and well tolerated; (ii) AAV2 subretinal administrations resulted in improvement of visual function in all trials although at different levels; (iii) in one trial there was evidence that the maximal efficacy was obtained in the youngest LCA2 patients, presumably with better retinal preservation. 31 Overall these results bode well for the development of AAV-based therapies for additional RPE-specific defects.
TRANSDUCTION BEYOND THE ILM: THE INNER RETINA AND AAV
Already early on, in some of first in vivo AAV gene transfer experiments to the retina, it was observed that following intravitreal injection AAV2 had the ability to transduce the retinal ganglion cells (RGC) lining the vitreous. 25 And that is where the field remained for several years; indeed, the first serotype comparison studies indicated that AAV2 but not AAV1 or AAV5 could target the retina from the vitreal side. 9, 73 In addition to RGCs, AAV2 also quite extensively transduced the trabecular meshwork and occasionally Müller cells. 9 In subsequent studies that included more of the natural serotypes and isolates, AAV6 emerged as another vector with potential to transduce the retina from the vitreal side. 74 Interestingly, these serotypes both bind heparin. 75, 76 Contrary to AAV2, in a quantitative study in the rat, AAV6 appears to distribute deeper in the inner nuclear layer where it can transduce amacrine, bipolar and Müller cells including those lining the retinal blood vessels. 74, 77 Müller glia are present throughout the entire retinal thickness and are vital to the neurons they are embedded in; they nourish, recycle neurotransmitters and photopigments, maintain osmotic homeostatis and protect against oxidative stress. Müller cells have a role in many forms of retinal degeneration and become activated under stress, which eventually may lead to gliosis. 78 Their central role in the retina makes them an important target for gene therapy. Other vectors with reported affinity for the inner retina are AAV isolates rh.8 and rh.10. 79 As mentioned previously, data is emerging that the ILM is a structural and biochemical barrier for AAV in a serotype-dependent manner, possibly due to the differential sequestration of AAV serotypes on the ILM by the presence of their cognate receptors. 23 These studies indicate a much broader pattern of expression with the natural AAV serotypes when the ILM is perturbed during the progression of retinal degeneration 23 or by an enzymatic digestion with Pronase E. 23 The authors argue that the barrier to transduction is unlikely to be diffusional or purely physical because some viruses, including some AAV serotypes, are able to cross the ILM fairly efficiently. Surgical or other routes to remove, bypass or avoid the ILM may indeed be the key for achieving efficient transduction via an intravitreal route.
The observation that some AAVs can, and some cannot penetrate the inner retina, validates approaches to alter the vector and thereby avoid the blocking of transduction by the ILM. Directed evolution for glial tropism, yielded several promising new vector candidates for Müller glia targeting in the retina. 22, 80 The rational design strategy of tyrosine modifications to the AAV capsid to improve transduction properties of existing serotypes has proven promising in this respect, with significant enhancement of AAV2's ability to target RGCs and Müller cells. In addition, in mouse, a few amacrine and rod bipolar cells can be targeted with these improved vectors. 18 Tyrosine modifications to AAV8 and AAV9 vectors also result in improved transduction following intravitreal injection, although AAV2 variants still appear to remain superior via this route. Single residue changes in these vectors, enabled transduction in a murine model at levels exceeding those of AAV2. 18 At higher doses, these vectors also demonstrate potential to penetrate to the outer retina and even the RPE to deliver their genetic payload. 19 It remains to be seen, however, whether these findings translate to larger animal models in which the ILM is considerably thicker compared with rodents.
CONCLUSIONS AND PROSPECTS
The last decade has seen exciting advances in the field of AAV vector development and application. The identification of dozens of naturally-occurring AAVs 81 and the parallel development of AAV variants based on either directed evolution 21 or rational mutagenesis 17 have created efficient gene transfer tools for a variety of target cells and tissues including the retina. Thanks to these developments, even the most aggressive types of retinal degeneration may become treatable. The demonstration of safety and efficacy of intraocular AAV administration in humans has provided a unique momentum for retinal gene therapy to move into the clinical arena. Although these results fuel the field with enthusiasm, some challenges remain, which will require additional technological developments to be overcome.
Rigorous comparison of the ability of the various AAV serotypes and variants to transduce specific cell types should be carried out in large animal models predictive of the behavior in the human retina (ideally the NHP as it is the only model with a macula). As expensive as this appears, it is a crucial step for the translation of the proof-ofconcept work established in the often-used smaller animal models of retinal diseases. Certain AAV serotypes, whereas efficient in these models, could actually be clinically irrelevant due to inter-species differences in transduction properties (or vice versa). In order to facilitate the use of AAV as a clinically-versatile vector for the treatment of IRD, irrespective of the causative gene or the severity of retinal atrophy, it is essential to identify the appropriate AAV serotypes for targeting each of the major retinal cell types in humans. To this end, in addition to in vivo administration to NHP, human retinal organ culture is attracting increasing interest as a tool to study AAV vector tropism and transduction characteristics. 82 Ultimately, one can envisage a scenario in which extensive efficacy testing in small animal models will no longer be required: one may develop a therapeutic AAV vector based on the most efficient serotype selected in NHP or human retinal culture, test its potency (that is, ability to express the therapeutic transgene) in explants and directly progress to production of vector under Good Manufacturing Practice standards and assessment of safety and toxicity before going into humans. This is clearly a discussion for scientists and regulators to address urgently, particularly for those IRDs that are lacking, or for which there are sub-optimal, animal models.
Although most of the focus in recent years has been placed on transduction of RPE and PR cells, an additional desirable target would be cells in the inner retina, such as bipolar neurons. Interest in inner retinal cells has increased because the recent observation that AAV-mediated gene transfer of microbial rhodopsins to inner retinal cells 83, 84 or to light-insensitive cones, 85 which are viable long after rods are lost in conditions such as retinitis pigmentosa, induce lightactivated responses and restore vision-driven behavior. This exciting approach, best described as a molecular prosthetic, in which one reprograms a cell to become light sensitive, may provide a gene-based therapeutic alternative for patient populations with complete loss of PR that would not benefit from more classical gene augmentation approaches. The ability of the small and penetrating AAV vectors to target the outer retina from the vitreal side may be an additional characteristic to further advance both pre-clinical and clinical retinal gene therapy given the ease of intravitreal administrations and the diffuse pattern of transduction that a single intravitreal administration can achieve. Finally, the efficient transfer of large genes to the retina using AAV vectors remains a challenge especially given that strategies such as those based on over-sized AAV vectors may not be clinically accepted until the high heterogeneity in genome size is reduced. Each of these challenges may be overcome by the development of AAV vectors with the appropriate capsid, the key determinant for AAV-mediated transduction. Rational design, directed evolution or in vivo phage bio-panning 86, 87 in which affinity peptides are inserted in the AAV capsid have proven to be powerful methods for vector engineering. Ultimately, cell-restricted gene expression will be required, preferably with cell-specific targeting by AAV, rather than with the currently used methods of transcriptional or post-transcriptional 88 control of gene expression.
In conclusion, the future of AAV-mediated retinal gene transfer appears bright as the increasing arsenal of AAV variants, whether natural or artificial, is proving an invaluable source of gene transfer vehicles for each specific need.
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